PMID- 37229352
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230528
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Associations Between Serum Folate Level and HOMA-IR in Chinese Patients with Type 
      2 Diabetes Mellitus.
PG  - 1481-1491
LID - 10.2147/DMSO.S409291 [doi]
AB  - BACKGROUND: Adequate intake of folic acid (FA) has been proven essential for 
      metabolism, cellular homeostasis, and antioxidant effects in diabetic patients. 
      Our aim was to evaluate the association between serum folate levels and the risk 
      of insulin resistance in patients with type 2 diabetes mellitus (T2DM) and to 
      provide new ideas and approaches for reducing the risk of T2DM. METHODS: This was 
      a case-control study involving 412 participants (206 with T2DM). Anthropometric 
      parameters, islet function, biochemical parameters and body composition of T2DM 
      group and control group were determined. Correlation analysis and logistic 
      regression were used to evaluate the risk factors associated with the onset of 
      insulin resistance in T2DM. RESULTS: The folate levels in type 2 diabetic 
      patients with insulin resistance were significantly lower than those in patients 
      without insulin resistance. Logistic regression showed that FA and high-density 
      lipoprotein were independent influencing factors for insulin resistance in 
      diabetic patients (P < 0.05). After adjusting for confounding factors, the degree 
      of insulin resistance in diabetic patients was in a significant inverse 
      relationship with folate levels (P< 0.05). We also found that below the serum FA 
      threshold of 7.09 ng/mL insulin resistance was significantly more elevated. 
      CONCLUSION: Our findings suggest that the risk of insulin resistance increases 
      with the decrease in serum FA levels in T2DM patients. Monitoring folate levels 
      in these patients and FA supplementation are warranted preventive measures.
CI  - (c) 2023 Yang et al.
FAU - Yang, Xiaoyue
AU  - Yang X
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
FAU - Hu, Rui
AU  - Hu R
AUID- ORCID: 0000-0002-7228-2225
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
FAU - Hou, Yilin
AU  - Hou Y
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
FAU - Song, Guangyao
AU  - Song G
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
AD  - Endocrinology Department, Hebei General Hospital, Shijiazhuang, Hebei, 050051, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230519
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10204713
OTO - NOTNLM
OT  - Chinese
OT  - folic acid
OT  - insulin resistance
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/05/25 19:12
MHDA- 2023/05/25 19:13
PMCR- 2023/05/19
CRDT- 2023/05/25 14:22
PHST- 2023/03/13 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/05/25 19:13 [medline]
PHST- 2023/05/25 19:12 [pubmed]
PHST- 2023/05/25 14:22 [entrez]
PHST- 2023/05/19 00:00 [pmc-release]
AID - 409291 [pii]
AID - 10.2147/DMSO.S409291 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 May 19;16:1481-1491. doi: 10.2147/DMSO.S409291. 
      eCollection 2023.